EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access

Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes

Janet A Lydecker iD, Ralitza Gueorguieva, Carlos M Grilo iD

Obesity · 2025

DOI: 10.1002/oby.24292 ↗

At a glance

Randomisierte kontrollierte Studie in Obesity, 2025. Written by Janet A Lydecker and 2 co-authors. Institution: Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA. Major MEDLINE topics: Behavior Therapy, Binge-Eating Disorder, Bupropion, Naltrexone. Cited 3 times so far (Crossref); 27 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NCATS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

The objective of this study was to examine rapid response and its prognostic significance in participants with binge‐eating disorder (BED) and obesity in a randomized clinical trial testing behavioral and pharmacological obesity treatments for BED.

Methods

A total of 136 participants were randomly assigned (balanced 2 × 2 factorial) to 16‐week behavioral and/or pharmacological (naltrexone/bupropion) obesity interventions. Masked assessments occurred monthly throughout treatment and at posttreatment.

Results

Rapid response (≥65% reduction in frequency of binge‐eating episodes after 1 month of treatment), observed in 55% ( n = 75/136) of participants, was unrelated to baseline sociodemographic and clinical characteristics. Rapid response was more common in behavioral therapy than not and in naltrexone/bupropion than placebo. Rapid response was associated with binge‐eating remission. Mixed models revealed that rapid response was associated with greater reductions in binge‐eating frequency, eating‐disorder psychopathology, percent weight loss, and metabolic variables (total cholesterol, glycated hemoglobin A1c ) at posttreatment. Rapid response effects on outcomes did not vary by treatment.

Conclusions

In a randomized clinical trial testing behavioral and pharmacological obesity treatments for BED with co‐occurring obesity, rapid response was a robust prognostic indicator of binge‐eating remission and significantly better behavioral, psychological, and metabolic outcomes. Non‐rapid response to behavioral and pharmacological obesity treatments could signal a need to switch to alternative treatments.

Subjects

MeSH terms (MEDLINE)

Behavior TherapyBinge-Eating DisorderBupropionNaltrexoneObesityAdultFemaleHumansMaleMiddle AgedGlycated HemoglobinTreatment OutcomeWeight Loss

Substances

BupropionGlycated HemoglobinNaltrexone

Authors and institutions

  • Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.

ORCID profiles: Janet A Lydecker, Carlos M Grilo

Funding

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advancing Translational Sciences

Cite

APA

Lydecker, J. A., Gueorguieva, R., & Grilo, C. M. (2025). Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes. Obesity. https://doi.org/10.1002/oby.24292

Vancouver

Lydecker JA, Gueorguieva R, Grilo CM. Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes. Obesity. 2025. doi:10.1002/oby.24292

BibTeX
@article{Lydecker2025,
  author = {Lydecker, Janet A and Gueorguieva, Ralitza and Grilo, Carlos M},
  title = {Rapid response to behavioral/pharmacological obesity treatments for binge‐eating disorder predicts better clinical outcomes},
  journal = {Obesity},
  year = {2025},
  doi = {10.1002/oby.24292}
}
Start for free →